Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Dosage Regimens: Designs and Approaches

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Drug Dosage Regimen: Overview

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Can ICER bring cost-effectiveness to drug prices?

Managed care (Langhorne, Pa.)·2019

Same author

A Mismatch Made in America.

Managed care (Langhorne, Pa.)·2019

Same author

Direct Contracting: Walmart Came a-Calling. Emory Answered.

Managed care (Langhorne, Pa.)·2019

Same author

Staying Mad: Walmart Gets Even-by Contracting Directly.

Managed care (Langhorne, Pa.)·2019

Same author

Prognosis? Misdiagnosis! The High Price of Getting It Wrong.

Managed care (Langhorne, Pa.)·2019

Same author

SOME DOCTORS FIND STRENGTH IN NUMBERS.

Physician leadership journal·2019

Same journal

Big pharma moves into biologics.

Biotechnology healthcare·2013

Same journal

Study: High Copayments Cut Biodrug Use up to 21 Percent.

Biotechnology healthcare·2013

Same journal

Avian flu and the quest for immunity: not just chicken feed.

Biotechnology healthcare·2013

Same journal

Variety of Biotech Therapies, Uses Take Prominence Among ASCO Presentations.

Biotechnology healthcare·2013

Same journal

Opening the door to follow-on proteins?

Biotechnology healthcare·2013

Same journal

On specialty pharmaceuticals: reflections of a second-year medical student.

Biotechnology healthcare·2013

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

8 lessons learned from part d.

Biotechnology Healthcare

|February 21, 2013

Summary

This summary is machine-generated.

Health plans faced challenges designing Medicare pharmacy benefits, particularly for biologics. Sharing common experiences and lessons learned is crucial for successful plan participation and managing high-cost medications.

More Related Videos

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Related Experiment Videos

Last Updated: May 14, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Area of Science:

Health Policy
Pharmaceutical Economics
Medicare Part D

Background:

Designing pharmacy-benefit packages for Medicare beneficiaries presents unique challenges, especially concerning high-cost biologic drugs.
Navigating the complexities of Medicare regulations and formularies requires strategic planning and adaptation.

Purpose of the Study:

To identify and analyze the common experiences of health plans in developing pharmacy-benefit packages for Medicare beneficiaries.
To highlight key lessons learned from these experiences that impact plan participation and success.

Main Methods:

Qualitative analysis of health plan experiences with Medicare pharmacy benefit design.
Case study approach examining common challenges and successful strategies.

Main Results:

Plans encountered significant hurdles in incorporating biologics into formularies.
Shared experiences revealed critical factors influencing plan competitiveness and beneficiary access.

Conclusions:

Understanding and applying lessons from common experiences are vital for health plans' effective participation in Medicare.
Strategic management of biologic coverage is a key determinant of success in Medicare pharmacy benefit design.